Site icon Kuvera

Cadila Share Price History and Analysis

Cadila Share Price

About Cadila

 

Cadila Healthcare Limited, incorporated and headquartered in India, operates as an integrated pharmaceutical corporation with operations spanning the whole value chain of pharmaceutical product research, development, production, marketing, and distribution. The company’s product line includes active pharmaceutical ingredients (API) and human formulations. The company’s stock is listed on the National Stock Exchange of India Limited (NSE) and the Bombay Stock Exchange Limited (BSE).

 

 

The company’s research and development objectives include New Chemical Entities (NCE), biologics, vaccines, speciality and complicated generic formulations, and API process development. The company has a global presence and sells its products in the United States, India, and Europe, as well as growing markets in Latin America, the Asia-Pacific region, and Africa. Modern, cost-effective, and regulatory-compliant manufacturing facilities assure a constant supply of high-quality products at the most competitive pricing to the company’s global clients.

 

The company is one of the leading innovation-driven pharmaceutical companies in India, with a presence across the entire pharmaceutical value chain, including R&D, manufacturing, marketing, and sales of finished dosage human formulations (generics, branded generics, and speciality formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. Innovation is the company’s backbone since it enables the ongoing availability of new products for various businesses, hence ensuring commercial viability.

 

Company’s History

 

Cadila Healthcare Ltd is a well-known, research-focused, technology-driven pharmaceutical company that focuses on biotechnology, formulations, and Active Pharmaceutical Ingredients. They are a multinational pharmaceutical company with headquarters in India. They have production plants in Gujarat in Ahmedabad, Ankleshwar, and Vadodara, in Goa at Ponda, in Maharashtra at Raigad, and in Himachal Pradesh at Solan.

 

Cadila Healthcare Ltd, the main company of Zydus Cadila Group, was established in May 1995 and went public in July 1996. Pharmaceuticals, including human formulations, veterinary formulations, bulk drugs, diagnostics, herbal goods, skin care products, and over-the-counter products, are part of the company’s operations.

 

In 1996, the company formed a strategic agreement with Gulin Pharma of China and marketed the anti-malarial drug Falcigo in India. In May of 2000, the company purchased Recon Ltd’s formulation business, strengthening its position in the southern region. In 2001, they purchased German Remedies, the largest merger and acquisition in the Indian pharmaceutical industry, and in the same year, they formed a joint venture with Onconova, a company based in the United States, for collaborative research in the field of oncogenomics.

 

In April 2002, the company purchased Banyan Chemicals, a Vadodara-based firm with an FDA-approved facility in the United States. German Remedies, Recon Healthcare, Zoom Properties, and Zydus Pathline amalgamated with the business in 2003. In addition, they purchased Alpharma France, which led the group’s operations in France. In the same year, the company became Schering AG’s “Partner of Choice” for manufacturing and marketing its products in India.

 

In November 2004, the company formed a strategic alliance with the Italian Zambon Group to expand its contract manufacturing opportunities. In the same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to produce and distribute BI’s products in India.

 

In 2005, the company formed a strategic agreement with Mallinckrodt Pharmaceuticals Generics, a business subsidiary of Tyco Healthcare, in order to promote the company’s product under a joint label. In the same year, the company formed a joint venture with Mayne Pharma of Australia to manufacture generic injectable cytotoxic (anti-cancer) drugs and active pharmaceutical ingredients (API) for international markets.

 

In 2005-2006, the company created a 50:50 joint venture with one of India’s leading biotech companies, Bharat Serums and Vaccines Ltd. (BSV), to develop, manufacture, and market a non-infringing and patented Novel Drug Delivery System (NDDS) of an approved anti-cancer medicine for worldwide markets.

 

During the 2006-2007 fiscal year, the company engaged in a share purchase agreement to buy a 97.95% ownership interest in Liva Healthcare Ltd., which manufactures and sells formulas. In Sikkim, a greenfield facility for Solid Oral Dosage Forms was constructed primarily for the domestic market. They also established a lyophilisation unit at the Moraiya plant with an annual capacity of seven and a half million doses to serve both the Indian and international markets.

 

During the 2007-2008 fiscal year, the business revamped its formulation division, Alidac, and introduced two new sub-divisions, Corza and Fortiza. In addition, they entered the nutraceutical market and founded Zydus Nutriva, a new division. The injectables factory in Moraiya has been upgraded, and its production facility in Ankleshwar has been extended.

 

To develop their branded business in Brazil, Zydus Healthcare Brasil Ltd, a wholly-owned subsidiary of the corporation, purchased 100% of the shares of Brazilian pharmaceutical company Quimica e Farmaceutica Nikkho Do Brasil Ltda. In addition, Zydus Pharmaceuticals Inc., Japan, a wholly-owned subsidiary of the corporation, bought 100% of the shares of Nippon Universal Pharmaceuticals Co., Ltd., a Japanese company that manufactures and markets pharmaceutical goods in Japan.

 

In February 2008, the company and Swedish Karo Bio entered into a three-year strategic partnership in the field of medication discovery and development. The company is in the midst of constructing a fine chemical facility in Dabhasa at a cost of approximately Rs 200 million, which will begin production in the 2008-2009 fiscal year.

 

In May 2008, the company entered the Spanish market by purchasing a 100% ownership interest in Laboratories Combix. In June 2008, the business would acquire a 70% majority stake in Simayla Pharmaceuticals of South Africa through its wholly-owned subsidiary, Zydus Healthcare SA Pty Ltd.

 

The company’s Consumer Products Division would be transferred to Carnation Nutra Analogue Foods Ltd, a subsidiary of Cadila Healthcare, and Zydus Hospital and Medical Research Pvt Ltd will be merged with the company.

 

Using monoclonal antibodies, the company entered into an agreement with WHO in August 2008 to examine the possibility of a collaboration in the development of a cocktail for the treatment of rabies.

 

Top Shareholder

 

Below is a list of the top shareholders of Cadila Share Price as of June 2022.

 

Shareholder No. of Shares  Shareholding (%)
Zydus Family Trust 75,87,88,706 74.96%
Kotak Flexicap Fund 2,53,16,795 2.50%
Life Insurance Corporation of India 6,42,67,147 6.35%
Resident Individuals holding nominal share capital up to Rs. 2 Lakhs 6,84,41,694 6.76%

 

Top Management

 

Below is a list of Cadila top management as of June 2022

Name  Designation
Mr. Pankaj R Patel  Chairman
Mr. Ganesh N Nayak Executive Director
Ms. Apurva S Diwanji Independent Director
Mr. Nitin R Desai Independent Director
Ms. Dharmishtaben N Raval Independent Woman Director
Dr. Sharvil P Patel Managing Director
Mr. Mukesh Patel Non-Executive Director
Mr. Nitin D Parekh  Chief Financial Officer
Mr. Dhaval N Soni Co. Secretary & Comp. Officer

 

Highlights From Cadila Healthcare Ltds Latest Quarterly Results – Q1 FY 23

 

 

 

 

 

 

 

Business Highlights

 

Formulation Business

 

 

 

 

 

Consumer Wellness Business

 

 

US formulations Business

 

 

 

 

 

 

 

Emerging Markets (EM) Pharmaceuticals Business

 

 

 

Europe’s formulations Business

 

 

API Business

 

 

Alliances and Others

 

 

Management’s Take

 

Dr. Sharvil Patel Managing Director, Zydus Lifesciences Limited said, “We are encouraged by our stable Q1 FY23 performance, particularly with the rebound in US business even as Consumer Wellness and Emerging Markets sustained growth momentum. India branded formulations business, adjusting for COVID impact delivered healthy growth and we expect to improve further. Focus on cost optimization helped us sustain 20% plus EBITDA margins amid input cost pressures. We continue to advance our innovation pipeline to build a strong foundation for the future. “

 

Why Should You Invest in Cadila Healthcare Ltd.?

 

According to NITI AAYOG, the Indian healthcare industry is anticipated to reach $372 billion by 2022, driven by rising incomes, better health awareness, lifestyle disorders, and expanding insurance coverage. Healthcare is now one of India’s top industries in terms of both revenue and jobs.

 

Hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment are included in healthcare. Primary care, secondary care, and tertiary care are the three major components of the Indian healthcare delivery system.

 

Primary care is the population’s initial point of contact with healthcare service providers. For instance, Sub-center (SC), Primary Health Centres (PHCs), and Community Health Centres (CHCs) are more pertinent to rural areas than Sub-center (SC).

 

Secondary care encompasses both inpatient and outpatient medical services, as well as straightforward surgical procedures. For instance, district hospitals and mid-sized hospitals.

 

The third level of the nation’s healthcare delivery system is tertiary care. These hospitals are infrastructure for specialized healthcare consultation. Hospitals with single or many specialities are examples.

 

In spite of the fact that both the public and private sectors offer healthcare services in urban and rural areas, people choose private hospitals over public hospitals for the treatment of disease, illness, and sickness. Therefore, let’s examine Zydus Lifesciences and its performance throughout time.

 

 

 

 

 

 

FAQ On Cadila Healthcare Ltd

 

 

Cadila  share price is INR 415.35  as of  14th October 2022. Cadila Healthcare Ltd has provided a return of approximately -15.57% in the past five years as of 14th October 2022.

 

As on 14th October 2022 Cadila Share Price are: 

 

Key metrics to analyse any share price are: a 52-week high, a 52-week low, a 1-year return, a 5-year return, etc. 

 

Peers of Cadila Healthcare Ltd include Sun Pharma, Cipla, Dr Reddys Lab, Abbott India etc.

 

The market cap of Cadila Healthcare Ltd is INR 42.04 Thousand crores as of 14th October 2022.
 

Interested in how we think about the markets?

 

Read more: Zen And The Art Of Investing

Watch/hear on YouTube:

 

 

Start investing through a platform that brings goal planning and investing to your fingertips. Visit Kuvera.in to discover Direct Plans and Fixed Deposits and start investing today.

Exit mobile version